This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations And Research

Stocks in this article: BPTH

Bio-Path Holdings, Inc., (OTCBB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Dr. Ana Maria Tari, PhD, MBA has been appointed Director, Preclinical Operations and Research. She will report to Peter Nielsen, President and Chief Executive Officer and be responsible for leading the Company’s evaluation and selection of new drug targets for licensing and development; design, source and direct preclinical in vitro and in vivo studies; and be the primary scientific liaison to the scientific community and clinical trial sites, including University of Texas M. D. Anderson Cancer Center.

Dr. Tari was a key member of the research team that performed the basic research and preclinical development of the liposomal delivery technology that Bio-Path has licensed from The University of Texas M. D. Anderson Cancer Center and is at the core of the Company’s research and development efforts. In particular, Dr. Tari was the lead researcher who developed the Company’s lead product candidate Liposomal Grb-2 (BP-100-1.01) that is currently in a Phase I clinical trial in blood cancers. Dr. Tari has authored or co-authored numerous articles in leading scientific journals, including several on the research done in Liposomal Grb-2. Previously, Dr. Tari has performed consulting work for the Company, being particularly instrumental in the transfer of licensed technology to the Company including manufacturing techniques, drug assays and testing methods.

Peter Nielsen, President and Chief Executive Officer of Bio-Path commented, “We are very fortunate to have Ana Tari join Bio-Path. Ana is a leader in the field of liposomal antisense therapeutics and will prove to be an invaluable resource as we develop and commercialize our proprietary neutral lipid delivery technology of which Ana was instrumental in developing. I look forward to working with Ana as we continue to advance our technology in our current clinical trial and her experience in the identification of new drug candidates and clinical trial design will be instrumental when we seek to expand into new drug targets.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs